Study of MLN8237 in Participants With Advanced Hematological Malignancies
Status:
Completed
Trial end date:
2016-10-19
Target enrollment:
Participant gender:
Summary
This is an open-label, multicenter, phase 1 study of MLN8237 in participants with advanced
hematological malignancies for whom there are limited standard treatment options.